The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-4.   (Cancelled)

5.   (Previously Presented)   A composition comprising 6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, a pharmaceutically acceptable carrier, and less than 0.2% by weight of said compound of the contaminants

and

6-8.   (Cancelled)

Atty. Docket. No.: Sch-1664-C01

9.   (Previously Presented)   A composition comprising 6ß, 7ß; 15ß, 16ß-dimethylene-3-oxo-17α -pregn-4-ene-21,17-carbolactone, a pharmaceutically acceptable carrier, and less than 0.2% by weight of said compound of the contaminants


and

X.

wherein X is an anion of an acid which is effective to open said 6β, 7β-methylene group.

10.   (Previously Presented)   A composition comprising

(a)   6β, 7β; 15β, 16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone made by a process comprising dehydrating a compound of Formula III,

Atty. Docket. No.: Sch-1664-C01

III

which was made by oxidizing in the presence of a ruthenium salt a compound of Formula

II,

II

which was made by catalytically hydrogenating a compound of Formula I

I

(b)   a pharmaceutically acceptable carrier, and

(c)   less than 0.2% by weight of said compound (a) of the byproducts of said

preparation process which are

and

X

wherein X is an anion of an acid which is effective to open said 6β, 7β-methylene group.

11.   (Cancelled)

12.   (Currently Amended) A ~~compound~~ composition of claim 10, wherein in said

process, said dehydrating is performed after said compound of Formula III is isolated from the

medium in which it is prepared.

13.   (Previously Presented)   6β, 7β; 15β, 16β-dimethylene-5β-hydroxy-3-oxo-

17α-androstane-21,17-carbolactone

in isolated form.

14.   (Previously Presented)   6β, 7β; 15β, 16β-dimethylene-5β-hydroxy-3-oxo-

17α-androstane-21,17-carbolactone

Atty. Docket. No.: Sch-1664-C01

in isolated and purified form.